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Human African trypanosomiasis is an infectious,
neglected, vector-borne protozoan disease which has an
early haemolymphatic phase followed by meningoen-
cephalitis due to neuroinvasion of the central nervous sys-
tem by trypanosomes. The determination of the earliest
timing when the blood-brain barrier (BBB) is breached
during neuropathogenesis of sleeping sickness has critical
implications on the choice of therapy, without which the
infection is fatal. Interleukin 10 (IL-10) and IgM have
been proposed as potentially important biomarkers when
this occurs. The vervet monkey is susceptible to experi-
mental infection with same aetiological agent as that
which causes HAT, providing a useful pathogenesis
model. Fourteen vervet monkeys were experimentally
infected with Trypanosoma brucei rhodesiense. The animals
were treated with diminazene aceturate (DA) and melar-
soprol (MelB) 28 and 140 days post infection (dpi),
respectively. Serum and CSF samples were obtained at
weekly intervals and assayed for immunospecific IgM and
IL-10 by ELISA. There was no detectable immunospecific
IgM in the CSF before 49 dpi. The CSF IgM increased pro-
gressively to peak levels that coincided with the appear-
ance of relapse parasites in blood 140 dpi. The serum IgM
levels increased significantly over control levels starting
21 dpi and peaked between 133 and 140 dpi. The serum
IL-10 levels increased rapidly and were significantly ele-
vated between 14 and 21 dpi. Following sub-curative
treatment with DA the serum IL-10 levels declined and
remained below detection limit until 127 dpi which coin-
cided with relapse of parasitaemia. A significant rise in
white cell counts in CSF was recorded starting 35 dpi.
When curative treatment with MelB was carried out, there
was a rapid decline of the three parameters leading to
attainment of preinfection levels of IgM and white cell
counts within 30 days. However CSF IgM levels remained
above pre-detection levels to the end of the study. We
were unable to measure/detect IL-10 in the CSF. Serum
and CSF concentrations of immunospecific IgM as well as
serum IL-10 changes follow a similar pattern that mimics
the progression of the disease and may present reliable ad
useful biomarkers of the disease stage.
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